This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Korsmeyer, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Korsmeyer, S. J.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, December 1999, p. 8469-8478, Vol. 19, No. 12
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

BCL-2 Is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway Normally Activated at G2/M

Kazuhito Yamamoto,1 Hidenori Ichijo,2 and Stanley J. Korsmeyer1,*

Departments of Pathology and Medicine, Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts 02115,1 and Department of Biomaterials Science, Faculty of Dentistry, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8549, Japan2

Received 21 July 1999/Accepted 14 September 1999


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Multiple signal transduction pathways are capable of modifying BCL-2 family members to reset susceptibility to apoptosis. We used two-dimensional peptide mapping and sequencing to identify three residues (Ser70, Ser87, and Thr69) within the unstructured loop of BCL-2 that were phosphorylated in response to microtubule-damaging agents, which also arrest cells at G2/M. Changing these sites to alanine conferred more antiapoptotic activity on BCL-2 following physiologic death signals as well as paclitaxel, indicating that phosphorylation is inactivating. An examination of cycling cells enriched by elutriation for distinct phases of the cell cycle revealed that BCL-2 was phosphorylated at the G2/M phase of the cell cycle. G2/M-phase cells proved more susceptible to death signals, and phosphorylation of BCL-2 appeared to be responsible, as a Ser70Ala substitution restored resistance to apoptosis. We noted that ASK1 and JNK1 were normally activated at G2/M phase, and JNK was capable of phosphorylating BCL-2. Expression of a series of wild-type and dominant-negative kinases indicated an ASK1/Jun N-terminal protein kinase 1 (JNK1) pathway phosphorylated BCL-2 in vivo. Moreover, the combination of dominant negative ASK1, (dnASK1), dnMKK7, and dnJNK1 inhibited paclitaxel-induced BCL-2 phosphorylation. Thus, stress response kinases phosphorylate BCL-2 during cell cycle progression as a normal physiologic process to inactivate BCL-2 at G2/M.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Programmed cell death plays an indispensable role in the development and maintenance of homeostasis within all multicellular organisms (62, 65). Genetic and molecular analysis of Caenorhabditis elegans to humans has indicated that the pathway of cellular suicide is highly conserved (14, 56). Although the capacity to carry out apoptosis appears to be inherent to all cells, their susceptibility varies markedly and is influenced by external and cell-autonomous events (49). Multiple steps in this process are subject to regulation, from cell surface death receptors to the BCL-2 family of proteins, to Apaf-1 and finally the caspases, which proteolytically cleave death substrates (10). Apoptosis has two predominant effector pathways, the activation of caspases and organelle dysfunction, of which mitochondrial dysfunction is best characterized (16). The BCL-2 family of proteins resides at a critical decisional point upstream to irreversible cellular damage, and the proteins focus much of their activities at the level of the mitochondria. The BCL-2 family possesses both pro- and antiapoptotic molecules, and their ratio determines, in part, the response to a death signal (44). Evidence that many of these molecules have inactive and active conformations has emerged. These transitions mediated by posttranslational modifications in response to death or survival signals are perhaps best characterized for the prodeath members.

Modifications to proapoptotic members include phosphorylation, dimerization, and proteolytic cleavage and often result in subcellular translocation. BAD belongs to a divergent "BH3 domain only" subset of the BCL-2 family, which possesses substantial sequence homology only within the BH3 amphipathic alpha  helix (46, 69). In the presence of survival factor, BAD is inactivated by phosphorylation on two serine residues (Ser112 and Ser136) and sequestered in the cytosol bound to 14-3-3 (70). Upon factor deprivation, BAD is activated by dephosphorylation and found associated with BCL-XL/BCL-2 at membrane sites including mitochondria. AKT/PKB/RAC, a Ser/Thr kinase downstream of phosphatidylinositol 3-kinase, is site specific for Ser136 of BAD (3, 11, 12). PKA is a BAD Ser112 site-specific kinase tethered to the outer mitochondrial membrane by an A-kinase anchoring protein which focuses this kinase-substrate interaction at the organelle where active BAD functions (22). Activation of the proapoptotic molecule BAX appears to involve subcellular translocation and dimerization (17, 24, 66). In viable cells, a substantial portion of BAX is monomeric and found either in the cytosol or loosely attached to membranes. Death stimuli result in the translocation of BAX to the mitochondria, where it is membrane integral and cross-linkable as a homodimer. Cytosolic BID is activated by caspase-8-mediated cleavage following tumor necrosis factor receptor 1/Fas death signals (18, 30, 34). The truncated p15 (tBID) targets mitochondria, and immunodepletion studies suggest that tBID is required for the release of cytochrome c. Structural insight into the active versus inactive conformation of BCL-2 family molecules has come from comparison of the three-dimensional structure of BID with that of BCL-XL (7, 38). One model posits that molecules with a buried hydrophobic face of the BH3 domain appear to be either antiapoptotic or inactive proapoptotic proteins. Active conformations can result from exposure of the BH3 domain and potentially other hydrophobic faces.

The founder of this family, antiapoptotic BCL-2, was discovered as a proto-oncogene at the chromosomal breakpoint of t(14;18)-bearing human B-cell lymphomas (1, 8, 60). BCL-2 is phosphorylated in response to multiple treatments, yet reports vary as to whether this modification activates or inactivates the molecule. BCL-2 is phosphorylated following exposure to the chemotherapeutic taxanes paclitaxel and taxotere, which promote microtubule assemblage (21). Phosphorylation appears to occur in an unstructured loop of BCL-2, as deletion of this loop eliminates paclitaxel-induced phosphorylation (5, 15, 54) and mutation of select serines reduces it (19). Deletion of this loop enhanced BCL-2 antiapoptotic ability, arguing that phosphorylation of BCL-2 inactivates the molecule. Paclitaxel binds peptides resembling the BCL-2 loop, suggesting a specific physical interaction among taxanes, microtubules, and a kinase for BCL-2 (51). However, the capacity of drugs including vincristine and vinblastine, which damage microtubules by other mechanisms, and even nocodazole to result in BCL-2 phosphorylation raises the possibility that this modification is related to a G2/M cell cycle block (32, 53). In contrast, interleukin-3 (IL-3), a growth and survival factor used in another cell system, results in the phosphorylation of BCL-2 (36, 47). This phosphorylation has been proposed to be either required for antiapoptotic function (27) or needed to relax the antiproliferative effect of BCL-2 (47). Multiple kinases have been proposed to mediate the phosphorylation of BCL-2 following these varied stimuli. These include paclitaxel-activated Raf-1 (2), bryostatin-1-induced mitochondrion-localized PKCalpha (52), paclitaxel or vincristine-induced PKA (55), or Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) when overexpressed or activated by paclitaxel (35, 54).

When we initiated this study, we believed it important to determine the precise sites of phosphorylation on BCL-2 induced by paclitaxel by using a combination of tryptic phosphopeptide mapping and sequencing. Three residues within the unstructured loop (Ser70, Ser87, and Thr69) were phosphorylated, and alteration of these sites to alanine conferred resistance to physiologic death signals as well as microtubule-damaging agents. We examined normal cycling cells enriched by elutriation for distinct phases of the cell cycle and found that BCL-2 is normally phosphorylated at G2/M. Moreover, G2/M-phase cells proved more susceptible to a Fas death signal, and a BCL-2 Ser70Ala mutant restored resistance. Examination of candidate kinases eliminated the cyclin B1-Cdc2 complex, revealing instead that the ASK1/JNK1 path was normally activated at G2/M phase. Expression of ASK1/JNK1 correctly phosphorylated BCL-2 in vivo, while dominant negative forms of ASK1, MKK7, and JNK1 (dnASK1, dnMKK7, and dnJNK1) inhibited paclitaxel-induced BCL-2 phosphorylation. Thus, stress-activated kinase inactivates BCL-2 at the G2/M phase during normal cell cycle progression as a physiologic process. Taxane treatment represents a convergence of G2/M arrest, microtubule polymerization, and JNK activation that also phosphorylates and inactivates BCL-2.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Plasmids. Mammalian expression plasmid for human BCL-2 (hBCL-2) in pSFFV was described previously (67). To replace Ser70, Ser87, or Thr69 with Ala, a PCR-based site-directed mutagenesis kit (Stratagene) was used. The expression vectors for the wild type (WT) and mutants were constructed in pSFFV or pcDNA3. The Ser70 Ser87 double mutant and Thr69 Ser70 Ser87 triple mutant (AA/A) were constructed by subcloning. The hBCL-2-His bacterial expression vector was made by replacing the C-terminal hydrophobic region of hBCL-2 with a synthetic oligonucleotide-encoding hexahistidine tag and subcloned in pET-25(+) vector. ASK1-hemagglutinin epitope (HA) and dnASK1-HA(K709R) in pcDNA3 were described elsewhere (25). MKK4 and Flag-p38(AGF) expression vectors were provided by R. J. Davis (13). HA-JNK1 expression vector was a gift from J. S. Gutkind (9). pSRalpha -SEK1-K116R and pSRalpha -JNK1-APF vectors were from G. L. Johnson (28). Plasmid pMT3-HA-p38 was a gift from J. Kyriakis (50). pSRalpha -MKK7 and pSRalpha -MKK7KL expression vectors were provided by E. Nishida (41). Bacterial glutathione S-transferase (GST)-MKK6(K/A) expression vector was kindly provided by H. Saito (58).

Stable transfections. Jurkat human T cells or WEHI-231 murine B cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES, 50 µM 2-mercaptoethanol, L-glutamine, penicillin, and streptomycin. WEHI-231JM cells were kindly provided by C. B. Thompson (5). Transfections with various constructs in pSFFV-neo were performed by electroporation of 20 µg of linearized plasmid into 107 cells at 950 µF and 200 V. After 48 h, selection with 1 mg of G418 per ml was started in 96-well plates. Neomycin (Neo)-resistant single-cell-originated clones were selected after 14 days.

Transient transfection assay. 293 cells were maintained in Iscove's modified Dulbecco's medium (GIBCO BRL) supplemented with 10% FBS, penicillin, and streptomycin. 293 cells grown in six-well dishes were transfected with the appropriate combinations of expression plasmids, using 8 µl of LipofectAMINE (GIBCO BRL). The total amount of plasmid DNA was kept at 1.75 µg by adding empty vector pcDNA3. Cells were harvested 24 h after transfection and, where indicated, treated with 1 µM paclitaxel for 8 h. The cell lysates were subjected to Western blot analysis.

Western blot analysis. Cells were lysed in 50 mM Tris (pH 7.5)-150 mM NaCl-2 mM EDTA-1 mM EGTA-1% Triton X-100 containing proteinase inhibitors (1 mM phenylmethylsulfonyl fluoride [PMSF], 2 µg of aprotinin per ml, and 2 µg of leupeptin per ml) and phosphatase inhibitors (50 mM NaF and 1 mM sodium orthovanadate), and cellular debris was removed by centrifugation at 14,000 × g. Samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a membrane. After blocking of the membrane with 3% milk and 2% bovine serum albumin in Dulbecco's phosphate-buffered saline (PBS) for 1 h, the membrane was incubated with primary and secondary antibodies (Abs) for 1 h each and developed with enhanced chemiluminescence (Amersham). Anti-hBCL-2 Abs 6C8 and Bcl-2/100 (Pharmingen) were used at 1 µg/ml, anti-HA Ab (12CA5; Boehringer Mannheim) was used at 2 µg/ml, anti-Flag Ab (Sigma) was used at 5 µg/ml, anti-JNK1 (C-17) and anti-SEK1/MKK4 (K-18) Abs (Santa Cruz Biotechnology) were used at 1:200, anti-human JNK1/JNK2 (G151-666) Ab (Pharmingen) was used at 1.5 µg/ml, and anti-phospho-SAPK/JNK Ab and anti-phospho-p38 mitogen-activated protein (MAP) kinase Ab (New England Biolabs) were used at 1:1,000.

Cell viability assay. Jurkat cells were treated with 0.001, 0.01, 0.1, or 1 µM paclitaxel (Sigma) or dimethyl sulfoxide (DMSO) (control) for 24 h, collected, and resuspended in 1 µg of propidium iodide (PI) per ml in PBS. Cell populations negative for PI measured with a FACScan (Becton Dickinson) were scored as viable. Jurkat cells were also treated with 100 ng of anti-Fas antibody CH-11 (Upstate Biotechnology) per ml, and cell viability was assayed by PI exclusion at indicated time points. WEHI-231 murine B cells were treated with the anti-immunoglobulin M (IgM) antibody BET-2 supernatant at 1:100 dilution.

Metabolic labeling and immunoprecipitation. Cells (107) were incubated in phosphate-free 10% FBS-RPMI 1640 medium and treated with 1 µM paclitaxel for Jurkat cells or 1 µM vincristine for WEHI-231 cells for 12 h, followed by the addition of 32P-orthophosphate at 2 mCi/ml. After 4 h of labeling, cells were washed with phosphate-free medium twice and lysed in radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 2 mM EDTA, 1 mM EGTA) with proteinase inhibitors (1 mM PMSF, 2 µg of aprotinin per ml, and 2 µg of leupeptin per ml) and phosphatase inhibitors (50 mM NaF and 1 mM sodium orthovanadate). The lysate was spun at 14,000 × g, and the supernatant was cleared with protein A beads for 30 min, followed by incubation with anti-hBCL-2 Ab 6C8 at 4°C for 1.5 h. The immune complex was captured with protein A beads for 1 h, washed with RIPA buffer four times, resuspended in loading buffer, and separated by SDS-PAGE. The separated samples were transferred to a membrane and visualized by autoradiography. The same membrane was also subjected to immunoblot analysis with Ab Bcl-2/100 (Pharmingen).

Phosphatase treatment of immunoprecipitated BCL-2. BCL-2 was immunoprecipitated with Ab 6C8 from 5 × 106 BCL-2-expressing Jurkat (Jurkat-BCL-2) cells treated with 1 µM paclitaxel. The immune complex was incubated with 400 U of lambda  protein phosphatase (lambda PPase) in 1× lambda PPase (50 mM Tris [pH 7.5], 0.1 mM EDTA, 5 mM dithiothreitol, 0.01% Brij 35) with or without phosphatase inhibitors (50 mM NaF, 2 mM sodium orthovanadate, 5 mM EDTA, 5 mM EGTA) at 30°C for 30 min. The reaction was terminated by adding SDS-PAGE loading buffer and boiling for 5 min. The resultant samples were separated on an SDS-14% polyacrylamide gel and subjected to immunoblot analysis.

Phosphoamino acid analysis and two-dimensional (2D) mapping. Immunoprecipitated BCL-2 from 32P-labeled Jurkat-BCL-2 cells was separated by SDS-PAGE and transferred to a membrane. The portion containing phosphorylated BCL-2 was excised after autoradiography, and the membrane was washed five times with deionized water. The analysis was performed by the method described by Boyle et al. (4), with minor modification.

For phosphoamino acid analysis, the BCL-2 on Immobilon-P (Millipore) was incubated in 200 µl of 6 N HCl (Pierce) at 110°C for 90 min. After evaporation of HCl, the samples were mixed with phosphoamino acid standard (1 µg each of cold phosphoserine, phosphothreonine, and phosphotyrosine [Sigma]) in pH 1.9 buffer (H2O-88% formic acid-glacial acetic acid, 897:25:78), and the mixtures were applied onto a thin-layer chromatography (TLC) plate (J. T. Baker) and separated with an HTLE-7000 electrophoresis system (CBS, Del Mar, Calif.). Electrophoresis was carried out in pH 1.9 buffer at 1,500 V for 30 min for the first-dimension separation and then in pH 3.5 buffer (H2O-acetic acid-pyridine, 945:50:5) at 1,300 V for 20 min for the second-dimension separation. Positions of phosphoamino acids were determined by ninhydrin (0.25% in acetone) staining.

For 2D mapping, a nitrocellulose membrane containing each phosphorylated BCL-2 species was treated with 0.5% PVP-360 (Sigma) in 100 mM acetic acid for 30 min at 37°C and then washed with deionized water five times and twice with 50 mM NH4HCO3. The proteins on the membrane were digested with 10 µg of tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin (Worthington Biochemicals) in 50 mM NH4HCO3 overnight at 37°C. The digestion was then carried out with another fresh 10 µg of TPCK-trypsin for an additional 2 h. Peptides were dried, washed once with deionized water, and then treated with performic acid on ice for 60 min. The resultant tryptic peptides were separated on a TLC plate in the first dimension by electrophoresis in pH 1.9 buffer at 1,000 V for 27 min at 4°C, followed by ascending chromatography in the second dimension in phospho-chromatography buffer (n-butanol-pyridine-acetic acid-H2O, 75:50:15:60). Autoradiography was used to visualize 32P-phosphopeptides.

For double digestion with TPCK-trypsin and proline-specific endopeptidase, the tryptic peptide was incubated with 3 U of proline-specific endopeptidase (ICN Biomedicals) overnight at 37°C in 50 mM NH4HCO3 (pH 7.6) followed by an additional 2-h incubation with 1 U of fresh enzyme. The digested peptides were oxidized with performic acid and then subjected to 2D mapping as described above.

To examine the comigration of a 32P-labeled tryptic peptide with a synthetic peptide, a mixture of tryptic 32P-phosphopeptides and 20 µg of the synthetic peptide bearing the corresponding phosphoamino acid were subjected to 2D mapping. Unlabeled peptides were visualized by ninhydrin.

Manual sequencing of 32P-phosphopeptide. The labeled peptides were scraped and eluted in pH 1.9 buffer from TLC plates, lyophilized, and resolved in 30% acetonitrile solution containing 0.1% trifluoroacetic acid. The peptides were then conjugated to a Sequelon-AA membrane at 55°C by using a Sequelon-AA reagent kit (Millipore). Manual Edman sequencing was performed as described previously (57), with minor modification. The primary change was a 55°C cleavage temperature instead of 50°C.

Centrifugal elutriations. Elutriations were performed as described previously (33), with minor modification. In brief, 5 × 108 Jurkat cells were injected into a Beckman JE-6B elutriation rotor and elutriated in RPMI 1640-0.5% FBS at 30°C at a constant rotor speed (2,100 rpm) with increasing flow rates from 9 to 35 ml/min. Fractions (100 to 150 ml) were collected and analyzed by FACScan for cell cycle position, and appropriate fractions were analyzed.

In vitro kinase assay. For measurement of JNK1 activity in vitro, 5 × 106 Jurkat cells were lysed in a lysis buffer (25 mM HEPES [pH 7.4], 150 mM NaCl, 20 mM beta -glycerophosphate, 2 mM EDTA, 2 mM EGTA, 50 mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100) with proteinase inhibitors (1 mM PMSF, 2 µg of aprotinin per ml, and 2 µg of leupeptin per ml). The lysates were clarified by centrifugation and immunoprecipitated with anti-JNK antibody C-17 (Santa Cruz Biotechnology) for 2 h. The immune complex was recovered with protein A-Sepharose beads (Sigma) and washed three times with lysis buffer and twice with kinase buffer (25 mM HEPES [pH 7.4], 20 mM MgCl2, 20 mM beta -glycerophosphate, 0.5 mM EGTA, 0.5 mM NaF, 0.5 mM sodium orthovanadate) with 1 mM PMSF. The immune complex on beads was divided into two aliquots; one was used for a kinase assay with GST-c-Jun (79) (Santa Cruz Biotechnology) as a substrate, and the other was used for assay with hBCL-2-His as a substrate. The reaction was initiated by adding 30 µl of kinase reaction mixture (kinase buffer plus 5 µCi of [gamma -32P]ATP, 20 µM unlabeled ATP, 1 mM DTT, and 1 µg of a substrate). After 20 min of incubation at 30°C, the reactions were terminated by addition of 10 µl of 4× SDS-PAGE loading buffer boiled for 5 min. Samples were resolved by SDS-PAGE and visualized by autoradiography or phosphorimaging. One-tenth of the immune complex on beads was used for immunoblot analysis to compare amounts of immunoprecipitated JNK. To measure Cdc2 kinase activity, anti-cyclin B1 Ab GNS-1 (Pharmingen) was used.

The immune complex kinase assay for endogenous ASK1 activity has been described previously (25, 43). Anti-ASK1 antiserum (DAV) was used for immunoprecipitation. GST-MKK6 and GST-p38gamma KN were used for coupled kinase assay, and GST-MKK6(K/A) was used for a single-step kinase assay.

Preparation of recombinant protein. hBCL-2-His protein was induced in Escherichia coli BL21(DE3) cells by adding 1 mM isopropyl-beta -D-thiogalactopyranoside and purified with Ni-nitrilotriacetic acid agarose (Qiagen) and a HiTrap Q column (Pharmacia Biotech). The preparation of GST-MKK6, GST-p38gamma KN, and GST-MKK6(K/A) has been described elsewhere (43, 58).


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Microtubule-damaging drugs induce BCL-2 mobility shifts due to phosphorylation on serine and threonine residues. Microtubule-damaging drugs including paclitaxel result in BCL-2 mobility shifts when assessed by SDS-PAGE and immunoblotting (Fig. 1A). To demonstrate that all of these shifts were due to phosphorylation, Jurkat-BCL-2 cells were labeled with 32P-orthophosphate, immunoprecipitated with anti-hBCL-2 Ab 6C8, and blotted to a membrane after SDS-PAGE. Three discrete bands detected by autoradiography corresponded precisely to the three mobility-shifted upper bands noted upon immunoblot development of the same membrane (Fig. 1A). Treatment of immunoprecipitated BCL-2 with lambda -PPase converted the shifted mobilities to the bottom, nonphosphorylated mobility (Fig. 1B). These data confirmed that all of the BCL-2 mobility shifts could be attributed to phosphorylation, and phosphorylation could be monitored by immunoblotting.


View larger version (28K):
[in this window]
[in a new window]
  		FIG. 1.   BCL-2 is phosphorylated on serine and threonine in vivo. (A) The mobility shift of BCL-2 induced by paclitaxel is due to phosphorylation. BCL-2 was immunoprecipitated from 32P-orthophosphate-labeled Jurkat-BCL-2 cells treated with paclitaxel (+) or DMSO (-) by using anti-hBCL-2 Ab 6C8, separated by SDS-PAGE, and transferred to a nitrocellulose membrane. After autoradiography, the same membrane was subjected to Western analysis with anti-hBCL-2 Ab Bcl-2/100. The three 32P-labeled bands (arrows) corresponded to three mobility-shifted bands by immunoblotting. The position of nonphosphorylated BCL-2 is indicated by a dash. (B) lambda PPase treatment of immunoprecipitated BCL-2. Immunoprecipitated BCL-2 from Jurkat-BCL-2 cells treated with paclitaxel was incubated with lambda PPase at 30°C for 30 min with or without phosphatase inhibitors (50 mM NaF, 2 mM sodium orthovanadate, 5 mM EDTA, and 5 mM EGTA). The resultant samples were subjected to Western blot analysis. (C) Phosphoamino acid analysis of BCL-2. BCL-2 was immunoprecipitated from 32P-labeled Jurkat-BCL-2 cells treated with paclitaxel, separated by SDS-PAGE, and transferred to a polyvinylidene difluoride membrane. Each radioactive band on the membrane (Fig. 1A) was hydrolyzed with hydrochloric acid. The amino acid composition was determined by 2D electrophoresis on TLC plates. Encircled areas indicate the locations of phosphoserine (P-Ser), phosphothreonine (P-Thr), and phosphotyrosine (P-Tyr), visualized by ninhydrin staining; 1, 2, and 3 represent results from bands 1, 2, and 3, respectively.

To determine which amino acid residues were phosphorylated, these three bands were subjected to phosphoamino acid analysis. In bands 1 and 2, serine residues were responsible for phosphorylation (Fig. 1C), whereas band 3 was phosphorylated on threonine in addition to serine residues (Fig. 1C). Thus, paclitaxel induces BCL-2 phosphorylation on serine and threonine residues.

Identification of Ser70, Ser87, and Thr69 in the loop region of BCL-2 as the phosphorylation sites. Of note, the intensity of band 2 was stronger than that of band 1 by autoradiography, while their intensities were comparable by Western analysis (Fig. 1A). Moreover, the ratio of the intensity of band 3 to that of band 1 was greater by autoradiography than by immunoblotting. These observations suggested bands 2 and 3 would possess multiple phosphorylation sites. To identify the precise phosphorylation sites, 2D mapping on TLC plates and manual Edman degradation sequencing of tryptic peptides of BCL-2 were performed. Immunoprecipitated BCL-2 from a lysate of in vivo-labeled Jurkat-BCL-2 cells was separated by SDS-PAGE and blotted to a nitrocellulose membrane, and bands 1, 2, and 3 were digested with trypsin. The tryptic peptides were separated on a TLC plate according to charge and hydrophobicity. Band 1 (Fig. 1A) revealed a single spot on 2D mapping (Fig. 2A) which, when subjected to manual sequencing, released the vast majority of the radioactivity, with a corresponding decrease of radioactivity bound to the membrane at the second cycle (Fig. 2B). BCL-2 possesses two tryptic peptides with a serine at position 2, located at amino acids 23 to 26 and 69 to 98. These could be distinguished because the former had no proline whereas the latter had seven. Double digestion with trypsin and proline-specific endopeptidase changed the migration of band 1 on TLC plates (data not shown), indicating that tryptic peptide 69-98 was phosphorylated and Ser70 was the phosphorylation site. The comigration of a synthetic peptide with a phospho-Ser70 confirmed this assignment (Fig. 2A).


View larger version (35K):
[in this window]
[in a new window]
  		FIG. 2.   Paclitaxel induces phosphorylation of Ser70, Ser87, and Thr69 in BCL-2 (A) 2D mapping and synthetic phosphopeptide comigration study of band 1. BCL-2 was immunoprecipitated from 32P-labeled Jurkat-BCL-2 cells treated with paclitaxel, size fractionated by SDS-PAGE, and transferred to a nitrocellulose membrane. The tryptic peptides of band 1 (Fig. 1A) were separated on a TLC plate by electrophoresis at pH 1.9 and chromatography. A synthetic pS70 phosphopeptide corresponding to band 1 migrated and was visualized on a TLC plate by ninhydrin staining. Moreover, the admixture of the pS70 peptide with the tryptic peptides revealed comigration on TLC plates (not shown). (B) Manual sequencing of tryptic phosphopeptide from band 1. The 32P-labeled peptide was eluted from the TLC plate, conjugated to a Sequelon-AA membrane, and subjected to manual Edman degradation. The radioactivity on the membrane (closed squares) or released into the liquid (open bars) was measured at the end of each cycle. (C and D) 2D mapping, synthetic phosphopeptide migration, and manual sequencing of band 2 as described above. (E and F) 2D mapping of synthetic phosphopeptide migration and manual sequencing of band 3 as described above. Tryptic peptides derived from bands 1, 2, and 3 were also eluted from the radioactive spots on TLC plates (A, C, and E) and subjected to phosphoamino acid analysis, confirming their composition.

Band 2 also revealed a single radioactive spot on 2D mapping (Fig. 2C). Manual sequencing revealed a decrease in radioactivity bound to the membrane, with corresponding release of 32P at the second cycle (Fig. 2D). However, approximately half of the radioactivity still remained on the membrane, indicating another phosphorylation site in the same tryptic peptide. Since phosphoamino acid analysis identified only serine residues (Fig. 1C), these findings together implicated Ser87 as the second phosphorylation site. Comigration of a synthetic peptide bearing phospho-Ser70 and phospho-Ser87 confirmed the assignment of these phosphorylation sites (Fig. 2C).

2D mapping of band 3 also revealed a single radioactive spot (Fig. 2E). Manual sequencing and comigration of a phospho-Thr69-, phospho-Ser70-, and phospho-Ser87-containing synthetic peptide identified the first position, Thr69, as the third phosphorylation site (Fig. 2E and F).

To confirm these assignments and in vivo usage of phosphorylation sites, we generated Jurkat human T-cell clones and WEHI-231 murine B-cell clones expressing WT hBCL-2, alanine-substituted Ser70 (S70A) or Ser87 (S87A), or all three phosphorylation sites including Thr69 plus the two Ser residues (AA/A). Cells were labeled in vivo with 32P-orthophosphate, and BCL-2 was immunoprecipitated with anti-hBCL-2 Ab 6C8. As shown in Fig. 3A, the S70A BCL-2 now demonstrated only one phosphorylated band. The S87A BCL-2 mutant demonstrated one prominent and one faint phosphorylation band in Jurkat cells and a single band in WEHI-231 cells. The BCL-2 triple mutant (AA/A) eliminated all phosphorylation of BCL-2. Thus, the phosphorylation of BCL-2 induced by microtubule-damaging drugs was within the unstructured loop region on Ser70, Ser87, and Thr69.


View larger version (33K):
[in this window]
[in a new window]
  		FIG. 3.   Substitution of phosphorylation sites in BCL-2 further enhances antiapoptotic activity. (A) Jurkat clones and WEHI-231 clones stably expressing WT or alanine-substituted phosphorylation sites of BCL-2, consisting of Ser70 (S70A), Ser87 (S87A), or all three phosphorylation sites, including Thr69 plus the two serines (AA/A), or an empty vector (Neo) were generated. Cells were treated with 1 µM paclitaxel for Jurkat clones or 1 µM vincristine for WEHI-231 clones and in vivo labeled with 32P-orthophosphate. BCL-2 was immunoprecipitated, separated by SDS-PAGE, and transferred to a membrane. After autoradiography, the same membranes were used for immunoblotting. Arrowheads denote phosphorylated BCL-2, and dashes denote nonphosphorylated BCL-2. The residual-shifted band on Western analysis of Jurkat cells bearing AA/A or Neo represents the endogenous hBCL-2 of Jurkat cells. (B) BCL-2 expression levels in Jurkat and WEHI-231 clones, determined by Western blot analysis of lysates from equivalent cells of various Jurkat or WEHI-231 clones with anti-hBCL-2 Ab 6C8 and anti-beta -actin Ab. (C to E) Cell viability assays of Jurkat clones (C and D) or WEHI-231 clones (E). Jurkat clones expressing comparable WT, S70A, S87A, AA/A BCL-2, or Neo control vector were stimulated with various doses of paclitaxel for 24 h (C) or anti-Fas antibody (100 ng/ml) (D), while WEHI-231 clones were treated with anti-IgM Ab (BET-2 supernatant at 1:100 dilution) (E). Viability was determined by PI exclusion using flow cytometry. The results represent the means of triplicate assays. Another independent set of clones expressing matched levels of WT or mutant BCL-2 showed comparable results.

Substitution of BCL-2 phosphorylation sites results in a gain of antiapoptotic function. To assess the relationship between BCL-2 phosphorylation and antiapoptotic function, Jurkat clones and WEHI-231 clones stably expressing comparable levels of WT BCL-2 and three BCL-2 mutants were identified (Fig. 3B). Jurkat clones were treated with a dose escalation of paclitaxel, and when assessed for viability, each clone showed dose-dependent cell death (Fig. 3C). WT BCL-2 conferred only minimal resistance compared to the Neo control (~35% versus ~28% at 1.0 µM paclitaxel). However, all three BCL-2 mutants demonstrated substantially stronger antiapoptotic function than WT BCL-2 following paclitaxel treatment. Jurkat clones expressing the three mutants S70A, S87A, and AA/A showed nearly identical enhancement of antiapoptotic function following anti-Fas Ab activation (~35 to 40% viability at 24 h) compared to WT BCL-2 (~15%) (Fig. 3D). All three mutated BCL-2 constructs were also more effective than WT BCL-2 in WEHI-231 cells treated with anti-IgM Ab (~45 to 50% versus ~30% at 72 h) (Fig. 3E). These data indicate that eliminating phosphorylation even at a single site (S87 or S70) improves antiapoptotic function of the molecule following a wide array of death stimuli.

Endogenous BCL-2 is normally phosphorylated at G2/M in cycling cells. Since paclitaxel arrests cells at the G2/M phase of the cell cycle, we asked whether its induction of BCL-2 phosphorylation might reflect an exaggerated response to a normally occurring phosphorylation of BCL-2 at G2/M. To assess whether BCL-2 is normally phosphorylated throughout the cell cycle, we examined the endogenous BCL-2 within Jurkat cells enriched for specific cell cycle stages by centrifugal elutriation. Elutriation-enriched G1-, S-, and G2/M-phase cells from asynchronously growing Jurkat T cells were assessed for BCL-2 phosphorylation. A mobility-shifted band typical of phosphorylation was prominent in the G2/M-phase population but much less intense in S phase and was not visible in G1-phase cells (Fig. 4A).


View larger version (16K):
[in this window]
[in a new window]
  		FIG. 4.   Phosphorylation of BCL-2 during the cell cycle. (A) Phosphorylation of endogenous BCL-2 at G2/M phase. Jurkat-Neo cells were elutriated to enrich for G1, S, and G2/M fractions and compared to asynchronous cells (Cont). Cellular lysates were subjected to immunoprecipitation (IP) with anti-BCL-2 monoclonal Ab 6C8 and the subsequent Western blot was developed with anti-hBCL-2 Ab Bcl-2/100. The percentages of cells in G1, S, and G2/M were determined by PI staining using FACScan and CELLQUEST software. (B) Ser70 was phosphorylated in cycling cells. Jurkat clones expressing WT, S70A, or S87A BCL-2 were elutriated and subjected to Western analysis. (C) Cells with phosphorylated BCL-2 at G2/M demonstrated increased susceptibility to apoptosis. Jurkat clones expressing WT or S70A BCL-2 were elutriated, and typical G1-, S-, and G2/M-enriched fractions were compared to asynchronous cells (Cont). Cells were treated with 100 ng of anti-Fas Ab per ml, and cell viability was determined by PI exclusion 6 h later. Values represent the relative viability of each fraction when the viability of the asynchronous cells is set at 100%. Values are the means of duplicate assays.

Ser70 is the principal site normally phosphorylated during the cell cycle. Endogenous BCL-2 from the G2/M-enriched fraction of Jurkat cells displayed only a single mobility-shifted band, consistent with a single phosphorylated site during normal cell cycle progression. To identify this phosphorylation site, Jurkat clones expressing WT, S70A, or S87A BCL-2 were elutriated, and cell cycle-enriched fractions were analyzed. One discrete mobility-shifted band was observed in the G2/M fraction of WT and S87A clones but not in the S70A clone, demonstrating that Ser70 is the major phosphorylation site in cycling cells (Fig. 4B).

To determine if cells vary in susceptibility to apoptosis throughout the cell cycle, the elutriated fractions were treated with anti-Fas Ab, and cell viability was determined. The G2/M-enriched cells expressing WT BCL-2 demonstrated an increased vulnerability to cell death (~155%) compared to the asynchronous population (considered the control and denoted as 100% relative cell death) (Fig. 4C). Evidence that this increased susceptibility at G2/M was attributable to the phosphorylation of BCL-2 was provided by the Jurkat clone expressing BCL-2 S70A. The presence of BCL-2 S70A restored resistance to the G2/M fraction of cells to an anti-Fas Ab stimulus (Fig. 4C).

Cyclin B1-Cdc2 is not a BCL-2 kinase. These findings suggest that endogenous BCL-2 is phosphorylated by a kinase activated at G2/M. An obvious candidate would be Cdc2, although the BCL-2 phosphorylation sites S70 and S87 only weakly match the phosphorylation consensus site for Cdc2 substrates (S/T-P-X-R>S/T-P) (40). To test this possibility, cellular lysates from elutriation-enriched G1, S, or G2/M fractions of Jurkat cells were immunoprecipitated with anti-cyclin B1 Ab, and an in vitro kinase assay was performed by using recombinant BCL-2-His or histone H1 as the substrate. Cdc2, as expected, was activated at G2/M and phosphorylated its classic substrate histone H1 but did not phosphorylate BCL-2 (Fig. 5A). This indicates Cdc2 is not the responsible kinase even though it has been shown to be activated by paclitaxel and participates in the apoptosis of breast cancer cells (68).


View larger version (29K):
[in this window]
[in a new window]
  		FIG. 5.   G2/M-activated ASK1-JNK1 pathway and JNK1 phosphorylation of BCL-2 in vitro. (A) G2/M-activated cyclin B1-Cdc2 complex does not phosphorylate BCL-2. Elutriated G1 (fraction [Fr] 3), S (Fr 8), and G2/M (Fr 11) fractions of Jurkat cells were lysed and immunoprecipitated (IP) with anti-cyclin B1. The phosphorylation of substrate histone H1 was assessed. The activity of this kinase complex for recombinant hBCL-2-His was also assessed. Arrowheads denote the position of the substrate. Cell cycle status was assayed by PI staining using a FACScan and CELLQUEST software. (B) Genistein and staurosporine inhibit paclitaxel-induced BCL-2 phosphorylation. Jurkat cells expressing WT BCL-2 were pretreated with various kinase inhibitors including 50 µM PD98059 (lane 3), 10 µM SB203580 (lane 4), 10 µM SB202190 (lane 5), 10 µg of genistein per ml (lane 6), 0.1 µM staurosporine (lane 7), 100 µM Rp-cAMP (lane 9), 10 µM LY294002 (lane 10), 1 µM wortmannin (lane 11), 20 ng of rapamycin per ml (lane 12), or DMSO (lanes 1, 2, and 8) for 60 min and then treated with (+) or without (-) paclitaxel for 6 h. BCL-2 phosphorylation was examined by Western blot analysis. (C) In vitro kinase (IVK) assay. The ASK1-JNK1 pathway is activated at the G2/M stage in cycling cells, and JNK1 phosphorylates BCL-2 in vitro. Lysates from elutriated fractions of Jurkat cells were immunoprecipitated with anti-ASK1 (DAV) serum or anti-JNK1 antibody. The ASK1 complex was incubated with GST-MKK6 and then with GST-p38gamma KN as a substrate to measure kinase activity. JNK activity was determined with GST-c-Jun (79) as a substrate. Recombinant hBCL-2-His was also incubated with the JNK1 complex. The position of substrates is denoted by open arrowheads. The fold activation of kinase activity is indicated as detected by phosphorimage analysis with activity at G1 set at 1.0. Western analysis of immunoprecipitates confirmed an equivalent amount of the kinase protein in each fraction (not shown).

To gain information about the BCL-2 kinase, we tested a series of kinase inhibitors to determine if they affected BCL-2 phosphorylation. Jurkat-BCL-2 cells were pretreated with various kinase inhibitors and subsequently exposed to paclitaxel (Fig. 5B). Staurosporine (a broad-spectrum Ser/Thr kinase inhibitor) and genistein (a Tyr kinase inhibitor) each markedly inhibited paclitaxel-induced BCL-2 phosphorylation. In contrast, phosphatidylinositol 3-kinase inhibitors (wortmannin and LY 294002), a MEK inhibitor (PD98059), p38 inhibitors (SB203580 and SB202190), a p70 S6 kinase inhibitor (rapamycin), and a PKA inhibitor (Rp-cAMP) did not substantially impair BCL-2 phosphorylation. Thus, this inhibitor study implicates both protein tyrosine kinase(s) and Ser/Thr kinase(s) in paclitaxel-induced BCL-2 phosphorylation.

ASK1 and JNK1 are activated at G2/M, and JNK1 phosphorylates BCL-2. BCL-2 phosphorylation sites conform to the consensus motif for substrates of MAP kinase and JNK/SAPK, yet the lack of response to kinase inhibitors (PD98059, SB203580, and SB202190) suggests that ERKs and p38 are not likely to be the BCL-2 kinase. Paclitaxel has been shown to result in JNK/SAPK activation (64). Its candidacy was supported by an immune complex kinase assay performed with endogenous JNK immunoprecipitated from Jurkat cells treated with anisomycin (10 µg/ml) or UV (300 J/m2) for 30 min. The immunoprecipitated, activated JNK phosphorylated recombinant BCL-2-His as well as its standard substrate GST-c-Jun (data not shown). Since BCL-2 was phosphorylated at G2/M in normally cycling cells, we next tested whether JNK was activated at G2/M and capable of phosphorylating BCL-2. JNK was immunoprecipitated from the cell cycle-enriched fractions of elutriated Jurkat cells and subjected to in vitro kinase assays. JNK from the G2/M fraction was threefold more active than at G1, as assayed with c-Jun as a substrate, and also proved more potent for phosphorylating recombinant BCL-2.

ASK1 is a member of the MAP3K (MAP kinase kinase kinase) subfamily which activates the JNK pathway and is required for tumor necrosis factor- and Fas-Daxx-induced apoptosis (6, 25). ASK1 has also been noted to be activated by microtubule-damaging agents (64). Consequently, we examined ASK1 activity within the cell cycle fractions of Jurkat cells. ASK1 activity was approximately sixfold higher at G2/M than at the G1 phase (Fig. 5C).

An ASK1/MKK7/JNK1 pathway is responsible for the phosphorylation of BCL-2 in vivo. To determine whether the ASK1-JNK pathway phosphorylated BCL-2 in vivo, we cotransfected 293 cells with an expression vector for BCL-2 together with an ASK1 vector and/or increasing amounts of a JNK1 vector. BCL-2 phosphorylation was induced by JNK1 in a dose-dependent manner but was dependent on the presence of ASK1 (Fig. 6A). The activation of exogenous JNK1 was confirmed by an anti-phospho-JNK-specific Ab (Fig. 6A). Transfection of ASK1 alone resulted in modest phosphorylation of BCL-2 mediated by activation of endogenous JNK (Fig. 6A). In contrast, p38 kinase with or without ASK1 cotransfection was not nearly as effective at phosphorylating BCL-2 (Fig. 6A), consistent with the kinase inhibitor data (Fig. 5B).


View larger version (33K):
[in this window]
[in a new window]
  		FIG. 6.   ASK1-JNK1 pathway phosphorylates BCL-2 in vivo. (A) Dose-dependent phosphorylation of BCL-2 by JNK1 in vivo. 293 cells were transfected with 20 ng of hBCL-2 or control vector together with indicated amounts of HA-ASK1, HA-JNK1, and/or HA-p38, as shown. The total amount of transfected DNA was kept constant by adding a compensating amount of empty vector pcDNA3. After 24 h, cells were lysed and the phosphorylation of BCL-2, expression level of each kinase, and activation of JNK and p38 were determined by Western analysis. Open arrowheads denote the activated endogenous JNKs (p46 and p54). (B) Substrate specificity of ASK1-JNK1 pathway in vivo. WT or phosphorylation site mutant BCL-2 expression vectors (20 ng) were cotransfected with ASK1 (500 ng) and JNK (750 ng) or pcDNA3 into 293 cells. Lysates generated 24 h after transfection were assessed for BCL-2 phosphorylation by Western analysis. (C) Inhibition of BCL-2 phosphorylation by dnASK1, dnMKK7, and dnJNK1. WT BCL-2 (20 ng) was cotransfected with dnASK1 (500 ng), dnSEK1 (500 ng), dnMKK7 (500 ng), and dnJNK1 (750 ng), as indicated, into 293 cells. The total amount of DNA transfected was normalized by adding pcDNA3. After 16 h, paclitaxel was added to a final concentration of 1 µM and cells were incubated an additional 8 h. BCL-2 phosphorylation and the expression levels of the dominant-negative (dn) kinases were determined by immunoblotting.

The accuracy of transfected ASK1/JNK1 in phosphorylating the correct sites of BCL-2 was examined by comparing cotransfections of mutant and WT BCL-2. ASK1/JNK1 resulted in two mobility-shifted bands of WT BCL-2, suggesting single and double phosphorylation of Ser70 and Ser87 (Fig. 6B). Consistent with this, the single-site mutants (S70A and S87A) revealed a single-shifted moiety. The lack of any mobility shift for the double (S70A S87A) or triple AA/A (T69A S70A S87A) mutants confirmed that ASK1/JNK1 phosphorylates the relevant BCL-2 sites normally phosphorylated at G2/M or by paclitaxel treatment.

To assess whether the endogenous ASK1/JNK1 pathway is responsible for BCL-2 phosphorylation, we used dominant-negative versions of kinases within this pathway (Fig. 6C). No single dominant-negative kinase expression vector was capable of inhibiting paclitaxel-induced phosphorylation of BCL-2. However, inhibition of multiple steps in the pathway by cotransfection of dnASK1, dnMKK7, and dnJNK1 together markedly inhibited BCL-2 phosphorylation. Of note, dnSEK1 was not as effective as dnMKK7 (Fig. 6C). These data support an ASK1/MKK7/JNK1 axis in the phosphorylation of BCL-2.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The phosphorylation of BCL-2 is a further example of how posttranslational modifications can interconvert active to inactive conformations of BCL-2 family molecules. However, uncertainty existed in the literature as to whether this phosphorylation activates (36) or inactivates (21) the antiapoptotic function of BCL-2. Consequently, we elected to first perform detailed 2D mapping and sequence identification of the in vivo phosphorylation sites on BCL-2 followed by their individual and collective substitution. Ser70, Ser87, and Thr69 proved to be phosphorylated, and all are located within the unstructured loop region between the alpha 1 and alpha 2 helices of BCL-2. The three mobility-shifted bands correspond to one, two, or three sites of phosphorylation, respectively. The number of phosphorylated sites appears to depend on the intensity of kinase activation. During normal cell cycle progression, Ser70 is the principal phosphorylation site. Haldar et al. (19) and Srivastava et al. (55) also noted Ser70 as the major site of phosphorylation in response to microtubule-damaging agents. We have also noted that following paclitaxel, Ser70 is phosphorylated before Ser87 (not shown) although this sequence of events is not obligate, as Ser87 is phosphorylated in an S70A mutant. The single S70A and S87A mutants and the triple AA/A mutant all demonstrate augmented antideath activity due to microtubule damage by paclitaxel or vincristine or to the physiologic anti-IgM or anti-Fas Ab signals. This evidence that BCL-2 phosphorylation is inactivating is in keeping with the observation that phosphorylated BCL-2 is less likely to heterodimerize with BAX molecules (47, 55). This is consistent with the initial proposal that the phosphorylation of BCL-2 would be inactivating (20). Our findings disagree with observations on a different system in which an S70A BCL-2 mutant displays less protection in NSF/N1.H7 cells, an IL-3-dependent cell line (27), although we found that the S70A mutant was capable of protecting another IL-3-dependent line, FL5.12 (44a). Of note, all BCL-2 mutants studied here (S70A, S87A, and the triple AA/A) demonstrate roughly comparable protection, which suggests that the three sites might act in concert to regulate BCL-2. Of interest, the protection offered by these mutants, including BCL-2 AA/A, which eliminates all phosphorylation, was not as complete as that reported for mutants lacking the unstructured loop (5, 54). While this might suggest modifications to the loop beyond phosphorylation, it is also conceivable that the loop deletion more effectively locks BCL-2 in an active conformation whereas phosphorylation only influences an equilibrium between active and inactive conformers.

The phosphorylation of BCL-2 at the G2/M phase of normally cycling cells indicates that the phosphorylation of BCL-2 is a normal physiologic process rather than exclusively a response to microtubule damage. The capacity of drugs with multiple actions, including nocodazole, taxanes and vinca alkaloids, to all result in BCL-2 phosphorylation suggests that arrest at G2/M might be the common event. What would be the purpose of inactivating BCL-2 at G2/M? Prior evidence of an interrelationship between cell cycle progression and BCL-2 exists. In IL-3-dependent cells, the phosphorylation of BCL-2 was temporally correlated with entry into the cell cycle (47). Bcl-2-deficient T cells demonstrated accelerated cell cycle entry but at the risk of increased apoptosis. In contrast, overexpression of BCL-2 delays entry into S phase and in T cells apparently at the restriction point, reflected by diminished IL-2 production upon activation (31, 37, 45, 61). If BCL-2 had a similar arresting affect at G2/M, phosphorylation might be required for its release. Alternatively, evidence presented here supports another model: that cells are more susceptible to a death signal during G2/M and that characteristic can be attributed to phosphorylation of BCL-2. Thus, a rationale for lowering the threshold for apoptosis at G2/M would be to ensure the elimination of cells with aberrations of chromosomal segregation. In support of this model, overexpression of BCL-XL has been noted to result in increased tetraploidization (39).

Our finding indicated that the same ASK1/JNK pathway is responsible for the normal cell cycle-related and paclitaxel-induced phosphorylation of BCL-2 (Fig. 7). This suggests that the phosphorylation of BCL-2 in response to the microtubule-damaging drugs could simply be an exaggerated normal process secondary to their G2/M arrest. Alternatively, a more intimate relationship could exist in that the same agents (taxanes, vinca alkaloids, nocodazole, and colchicine) that result in the phosphorylation of BCL-2 also activate the ASK1/JNK kinase pathway (64). In our examination, no single dominant negative kinase in this pathway was capable of blocking paclitaxel-induced phosphorylation of BCL-2, consistent with other observations (63). However, combined dominant negatives for each step of the pathway (dnASK1/dnMKK7/dnJNK1) interfered quite effectively with BCL-2 phosphorylation. Consistent with this, the combined overexpression of WT ASK1/JNK1 was capable of phosphorylating BCL-2 in vivo. The JNK family has been reported to mediate both proapoptotic and antiapoptotic responses, perhaps reflecting cell type specificity (26). This is supported by Jnk1/Jnk2 double-deficient embryos, which revealed region-specific apoptosis with reduced death in the hindbrain but increased apoptosis in the forebrain (29). Neither SEK1 nor p38 had obvious effects despite the fact that p38 is implicated as a component of the mitotic spindle checkpoint (59). Recently, activated JNK1/2 has been shown to colocalize with a MAP3K, MLK (mixed lineage) Ser/Thr kinase, to punctate structures along microtubules. Of potential interest, MLK interacts with the KIF3 family of kinesin motor proteins (42). In further support of a direct relationship between microtubules and the cell death pathway, another BCL-2 family member BIM binds to the LC8 dynein light-chain protein (48). In this context, organelles including mitochondria are transported along microtubules by means of microtubule-associated motor proteins (23). BCL-2 localizes to mitochondria, endoplasmic reticulum, and nuclear envelope, and transportation along microtubules arranges these organelles on a metaphase plate to allow equal segregation of them to daughter cells at mitosis. Thus, BCL-2 associated with these organelles could be placed in apposition with activated JNK pathway kinases found at microtubules. Thus, drugs which cause microtubule dysfunction would be activating the same MAP3K/JNK pathway, prompting the phosphorylation of a normal substrate(s) including BCL-2 (Fig. 7).


View larger version (23K):
[in this window]
[in a new window]
  		FIG. 7.   Schematic representation of the ASK1/MKK7/JNK1 pathway in BCL-2 phosphorylation. ASK1, a MAP3K, is activated by extracellular and intracellular stimuli to induce JNK pathway activation. JNK phosphorylates BCL-2, inactivating its antiapoptotic function. TNFR1, tumor necrosis factor receptor 1.


    ACKNOWLEDGMENTS

We are grateful to R. J. Davis, S. Gutkind, G. L. Johnson, J. Kyriakis, E. Nishida, and H. Saito for providing the expression vectors described above and to Steven F. Dowdy, David S. Pellman, Mark Dalton, and Zoltan Oltvai for technical advice and scientific discussion. We also thank Deborah S. Maher for secretarial assistance.

K.Y. was a fellow of the National Cancer Institute (U.S.A.)-Japanese Foundation for Cancer Research Research Training Program and is supported in part by the Uhehara Memorial Foundation Research Fellowship.


    FOOTNOTES

* Corresponding author. Mailing address: Departments of Pathology and Medicine, Harvard Medical School and Dana-Farber Cancer Institute, One Jimmy Fund Way, Boston, MA 02115. Phone: (617) 632-6402. Fax: (617) 632-6401. E-mail: stanley_korsmeyer{at}dfci.harvard.edu.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Bakhshi, A., J. P. Jensen, P. Goldman, J. J. Wright, O. W. McBride, A. L. Epstein, and S. J. Korsmeyer. 1985. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41:899-906[Medline].
2. Blagosklonny, M. V., P. Giannakakou, W. S. el-Deiry, D. G. Kingston, P. I. Higgs, L. Neckers, and T. Fojo. 1997. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 57:130-135[Abstract/Free Full Text].
3. Blume-Jensen, P., R. Janknecht, and T. Hunter. 1998. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr. Biol. 8:779-782[Medline].
4. Boyle, W. J., P. van der Geer, and T. Hunter. 1991. Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol. 201:110-149[Medline].
5. Chang, B. S., A. J. Minn, S. W. Muchmore, S. W. Fesik, and C. B. Thompson. 1997. Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J. 16:968-977[Medline].
6. Chang, H. Y., H. Nishitoh, X. Yang, H. Ichijo, and D. Baltimore. 1998. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 281:1860-1863[Abstract/Free Full Text].
7. Chou, J. J., H. Li, G. S. Salvesen, J. Yuan, and G. Wagner. 1999. Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 96:615-624[Medline].
8. Cleary, M. L., and J. Sklar. 1985. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. USA 82:7439-7443[Abstract/Free Full Text].
9. Coso, O. A., M. Chiariello, J. C. Yu, H. Teramoto, P. Crespo, N. Xu, T. Miki, and J. S. Gutkind. 1995. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 81:1137-1146[Medline].
10. Cryns, V., and J. Yuan. 1998. Proteases to die for. Genes Dev. 12:1551-1570[Free Full Text].
11. Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M. E. Greenberg. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241[Medline].
12. del Peso, L., M. Gonzalez-Garcia, C. Page, R. Herrera, and G. Nunez. 1997. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278:687-689[Abstract/Free Full Text].
13. Derijard, B., J. Raingeaud, T. Barrett, I. H. Wu, J. Han, R. J. Ulevitch, and R. J. Davis. 1995. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267:682-685[Abstract/Free Full Text].
14. Ellis, R. E., J. Y. Yuan, and H. R. Horvitz. 1991. Mechanisms and functions of cell death. Annu. Rev. Cell Biol. 7:663-698.
15. Fang, G., B. S. Chang, C. N. Kim, C. Perkins, C. B. Thompson, and K. N. Bhalla. 1998. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res. 58:3202-3208[Abstract/Free Full Text].
16. Green, D. R., and J. C. Reed. 1998. Mitochondria and apoptosis. Science 281:1309-1312[Abstract/Free Full Text].
17. Gross, A., J. Jockel, M. C. Wei, and S. J. Korsmeyer. 1998. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 17:3878-3885[Medline].
18. Gross, A., X. M. Yin, K. Wang, M. C. Wei, J. Jockel, C. Milliman, H. Erdjument-Bromage, P. Tempst, and S. J. Korsmeyer. 1999. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274:1156-1163[Abstract/Free Full Text].
19. Haldar, S., A. Basu, and C. M. Croce. 1998. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res. 58:1609-1615[Abstract/Free Full Text].
20. Haldar, S., J. Chintapalli, and C. M. Croce. 1996. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1253-1255[Abstract/Free Full Text].
21. Haldar, S., N. Jena, and C. M. Croce. 1995. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA 92:4507-4511[Abstract/Free Full Text].
22. Harada, H., B. Becknell, M. Wilm, M. Mann, L. J. Huang, S. S. Taylor, J. D. Scott, and S. J. Korsmeyer. 1999. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol. Cell 3:413-422[Medline].
23. Hirokawa, N. 1998. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 279:519-526[Abstract/Free Full Text].
24. Hsu, Y. T., K. G. Wolter, and R. J. Youle. 1997. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc. Natl. Acad. Sci. USA 94:3668-3672[Abstract/Free Full Text].
25. Ichijo, H., E. Nishida, K. Irie, P. ten Dijke, M. Saitoh, T. Moriguchi, M. Takagi, K. Matsumoto, K. Miyazono, and Y. Gotoh. 1997. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275:90-94[Abstract/Free Full Text].
26. Ip, Y. T., and R. J. Davis. 1998. Signal transduction by the c-Jun N-terminal kinase (JNK)---from inflammation to development. Curr. Opin. Cell Biol. 10:205-219[Medline].
27. Ito, T., X. Deng, B. Carr, and W. S. May. 1997. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 272:11671-11673[Abstract/Free Full Text].
28. Johnson, N. L., A. M. Gardner, K. M. Diener, C. A. Lange-Carter, J. Gleavy, M. B. Jarpe, A. Minden, M. Karin, L. I. Zon, and G. L. Johnson. 1996. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. J. Biol. Chem. 271:3229-3237[Abstract/Free Full Text].
29. Kuan, C. Y., D. D. Yang, D. R. Samanta Roy, R. J. Davis, P. Rakic, and R. A. Flavell. 1999. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22:667-676[Medline].
30. Li, H., H. Zhu, C. J. Xu, and J. Yuan. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501[Medline].
31. Linette, G. P., Y. Li, K. Roth, and S. J. Korsmeyer. 1996. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc. Natl. Acad. Sci. USA 93:9545-9552[Abstract/Free Full Text].
32. Ling, Y. H., C. Tornos, and R. Perez-Soler. 1998. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem. 273:18984-18991[Abstract/Free Full Text].
33. Lissy, N. A., L. F. Van Dyk, M. Becker-Hapak, A. Vocero-Akbani, J. H. Mendler, and S. F. Dowdy. 1998. TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point. Immunity 8:57-65[Medline].
34. Luo, X., I. Budihardjo, H. Zou, C. Slaughter, and X. Wang. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-490[Medline].
35. Maundrell, K., B. Antonsson, E. Magnenat, M. Camps, M. Muda, C. Chabert, C. Gillieron, U. Boschert, E. Vial-Knecht, J. C. Martinou, and S. Arkinstall. 1997. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J. Biol. Chem. 272:25238-25242[Abstract/Free Full Text].
36. May, W. S., P. G. Tyler, T. Ito, D. K. Armstrong, K. A. Qatsha, and N. E. Davidson. 1994. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J. Biol. Chem. 269:26865-26870[Abstract/Free Full Text].
37. Mazel, S., D. Burtrum, and H. T. Petrie. 1996. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J. Exp. Med. 183:2219-2226[Abstract/Free Full Text].
38. McDonnell, J. M., D. Fushman, C. L. Milliman, S. J. Korsmeyer, and D. Cowburn. 1999. Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. Cell 96:625-634[Medline].
39. Minn, A. J., L. H. Boise, and C. B. Thompson. 1996. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10:2621-2631[Abstract/Free Full Text].
40. Moreno, S., and P. Nurse. 1990. Substrates for p34cdc2: in vivo veritas? Cell 61:549-551[Medline].
41. Moriguchi, T., F. Toyoshima, N. Masuyama, H. Hanafusa, Y. Gotoh, and E. Nishida. 1997. A novel SAPK/JNK kinase, MKK7, stimulated by TNFalpha and cellular stresses. EMBO J. 16:7045-7053[Medline].
42. Nagata, K., A. Puls, C. Futter, P. Aspenstrom, E. Schaefer, T. Nakata, N. Hirokawa, and A. Hall. 1998. The MAP kinase kinase kinase MLK2 co-localizes with activated JNK along microtubules and associates with kinesin superfamily motor KIF3. EMBO J. 17:149-158[Medline].
43. Nishitoh, H., M. Saitoh, Y. Mochida, K. Takeda, H. Nakano, M. Rothe, K. Miyazono, and H. Ichijo. 1998. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol. Cell 2:389-395[Medline].
44. Oltvai, Z. N., and S. J. Korsmeyer. 1994. Checkpoints of dueling dimers foil death wishes. Cell 79:189-192[Medline].
44a. Oltvai, Z. N., and S. J. Korsmeyer. Unpublished observation.
45. O'Reilly, L. A., D. C. Huang, and A. Strasser. 1996. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 15:6979-6990[Medline].
46. Ottilie, S., J. L. Diaz, W. Horne, J. Chang, Y. Wang, G. Wilson, S. Chang, S. Weeks, L. C. Fritz, and T. Oltersdorf. 1997. Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins. J. Biol. Chem. 272:30866-30872[Abstract/Free Full Text].
47. Poommipanit, P., B. Chen, and Z. N. Oltvai. 1999. Interleukin-3 induces the phosphorylation of a distinct fraction of bcl-2. J. Biol. Chem. 274:1033-1039[Abstract/Free Full Text].
48. Puthalakath, H., D. C. Huang, L. A. O'Reilly, S. M. King, and A. Strasser. 1999. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell 3:287-296[Medline].
49. Raff, M. C. 1992. Social controls on cell survival and cell death. Nature 356:397-400[Medline].
50. Rana, A., K. Gallo, P. Godowski, S. Hirai, S. Ohno, L. Zon, J. M. Kyriakis, and J. Avruch. 1996. The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. J. Biol. Chem. 271:19025-19028[Abstract/Free Full Text].
51. Rodi, D. J., R. W. Janes, H. J. Sanganee, R. A. Holton, B. A. Wallace, and L. Makowski. 1999. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J. Mol. Biol. 285:197-203[Medline].
52. Ruvolo, P. P., X. Deng, B. K. Carr, and W. S. May. 1998. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 273:25436-25442[Abstract/Free Full Text].
53. Scatena, C. D., Z. A. Stewart, D. Mays, L. J. Tang, C. J. Keefer, S. D. Leach, and J. A. Pietenpol. 1998. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem. 273:30777-30784[Abstract/Free Full Text].
54. Srivastava, R. K., Q. S. Mi, J. M. Hardwick, and D. L. Longo. 1999. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. USA 96:3775-3780[Abstract/Free Full Text].
55. Srivastava, R. K., A. R. Srivastava, S. J. Korsmeyer, M. Nesterova, Y. S. Cho-Chung, and D. L. Longo. 1998. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol. 18:3509-3517[Abstract/Free Full Text].
56. Steller, H. 1995. Mechanisms and genes of cellular suicide. Science 267:1445-1449[Abstract/Free Full Text].
57. Sullivan, S., and T. W. Wong. 1991. A manual sequencing method for identification of phosphorylated amino acids in phosphopeptides. Anal. Biochem. 197:65-68[Medline].
58. Takekawa, M., and H. Saito. 1998. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 95:521-530[Medline].
59. Takenaka, K., T. Moriguchi, and E. Nishida. 1998. Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science 280:599-602[Abstract/Free Full Text].
60. Tsujimoto, Y., J. Cossman, E. Jaffe, and C. M. Croce. 1985. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443[Abstract/Free Full Text].
61. Vairo, G., K. M. Innes, and J. M. Adams. 1996. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 13:1511-1519[Medline].
62. Vaux, D. L., and S. J. Korsmeyer. 1999. Cell death in development. Cell 96:245-254[Medline].
63. Wang, T. H., D. M. Popp, H. S. Wang, M. Saitoh, J. G. Mural, D. C. Henley, H. Ichijo, and J. Wimalasena. 1999. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J. Biol. Chem. 274:8208-8216[Abstract/Free Full Text].
64. Wang, T. H., H. S. Wang, H. Ichijo, P. Giannakakou, J. S. Foster, T. Fojo, and J. Wimalasena. 1998. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J. Biol. Chem. 273:4928-4936[Abstract/Free Full Text].
65. White, E. 1996. Life, death, and the pursuit of apoptosis. Genes Dev. 10:1-15[Free Full Text].
66. Wolter, K. G., Y. T. Hsu, C. L. Smith, A. Nechushtan, X. G. Xi, and R. J. Youle. 1997. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 139:1281-1292[Abstract/Free Full Text].
67. Yin, X. M., Z. N. Oltvai, and S. J. Korsmeyer. 1994. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321-323[Medline].
68. Yu, D., T. Jing, B. Liu, J. Yao, M. Tan, T. J. McDonnell, and M. C. Hung. 1998. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol. Cell 2:581-591[Medline].
69. Zha, J., H. Harada, K. Osipov, J. Jockel, G. Waksman, and S. J. Korsmeyer. 1997. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J. Biol. Chem. 272:24101-24104[Abstract/Free Full Text].
70. Zha, J., H. Harada, E. Yang, J. Jockel, and S. J. Korsmeyer. 1996. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619-628[Medline].

Molecular and Cellular Biology, December 1999, p. 8469-8478, Vol. 19, No. 12
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Arachiche, A., Kerbiriou-Nabias, D., Garcin, I., Letellier, T., Dachary-Prigent, J. (2009). Rapid Procoagulant Phosphatidylserine Exposure Relies on High Cytosolic Calcium Rather Than on Mitochondrial Depolarization. Arterioscler. Thromb. Vasc. Bio. 29: 1883-1889 [Abstract] [Full Text]  
  • Cazanave, S. C., Mott, J. L., Elmi, N. A., Bronk, S. F., Werneburg, N. W., Akazawa, Y., Kahraman, A., Garrison, S. P., Zambetti, G. P., Charlton, M. R., Gores, G. J. (2009). JNK1-dependent PUMA Expression Contributes to Hepatocyte Lipoapoptosis. J. Biol. Chem. 284: 26591-26602 [Abstract] [Full Text]  
  • Kutuk, O., Arisan, E. D., Tezil, T., Shoshan, M. C., Basaga, H. (2009). Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. Carcinogenesis 30: 1517-1527 [Abstract] [Full Text]  
  • Resch, U., Schichl, Y. M., Winsauer, G., Gudi, R., Prasad, K., de Martin, R. (2009). Siva1 is a XIAP-interacting protein that balances NF{kappa}B and JNK signalling to promote apoptosis. J. Cell Sci. 122: 2651-2661 [Abstract] [Full Text]  
  • Saadeddin, A., Babaei-Jadidi, R., Spencer-Dene, B., Nateri, A. S. (2009). The Links between Transcription, {beta}-catenin/JNK Signaling, and Carcinogenesis. Mol Cancer Res 7: 1189-1196 [Abstract] [Full Text]  
  • Kolliputi, N., Waxman, A. B. (2009). IL-6 cytoprotection in hyperoxic acute lung injury occurs via PI3K/Akt-mediated Bax phosphorylation. Am. J. Physiol. Lung Cell. Mol. Physiol. 297: L6-L16 [Abstract] [Full Text]  
  • ENGSTROM, W., GRANERUS, M. (2009). Expression of JNK-interacting Protein JIP-1 and Insulin-like Growth Factor II in Wilms Tumour Cell Lines and Primary Wilms Tumours. Anticancer Res 29: 2467-2472 [Abstract] [Full Text]  
  • Fang, X., Feng, Y., Shi, Z., Dai, J. (2009). Alterations of Cytokines and MAPK Signaling Pathways are Related to the Immunotoxic Effect of Perfluorononanoic Acid. Toxicol Sci 108: 367-376 [Abstract] [Full Text]  
  • Faustin, B., Chen, Y., Zhai, D., Negrate, G. L., Lartigue, L., Satterthwait, A., Reed, J. C. (2009). Mechanism of Bcl-2 and Bcl-XL inhibition of NLRP1 inflammasome: Loop domain-dependent suppression of ATP binding and oligomerization. Proc. Natl. Acad. Sci. USA 106: 3935-3940 [Abstract] [Full Text]  
  • Xie, P., Guo, S., Fan, Y., Zhang, H., Gu, D., Li, H. (2009). Atrogin-1/MAFbx Enhances Simulated Ischemia/Reperfusion-induced Apoptosis in Cardiomyocytes through Degradation of MAPK Phosphatase-1 and Sustained JNK Activation. J. Biol. Chem. 284: 5488-5496 [Abstract] [Full Text]  
  • Pattingre, S., Bauvy, C., Carpentier, S., Levade, T., Levine, B., Codogno, P. (2009). Role of JNK1-dependent Bcl-2 Phosphorylation in Ceramide-induced Macroautophagy. J. Biol. Chem. 284: 2719-2728 [Abstract] [Full Text]  
  • Kim, I., Shu, C.-W., Xu, W., Shiau, C.-W., Grant, D., Vasile, S., Cosford, N. D. P., Reed, J. C. (2009). Chemical Biology Investigation of Cell Death Pathways Activated by Endoplasmic Reticulum Stress Reveals Cytoprotective Modulators of ASK1. J. Biol. Chem. 284: 1593-1603 [Abstract] [Full Text]  
  • Deng, X., Gao, F., May, W. S. (2009). Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood 113: 422-428 [Abstract] [Full Text]  
  • Nakamura, K., Abarzua, F., Hongo, A., Kodama, J., Nasu, Y., Kumon, H., Hiramatsu, Y. (2009). Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer. Ann Oncol 20: 63-70 [Abstract] [Full Text]  
  • Upreti, M., Galitovskaya, E. N., Chu, R., Tackett, A. J., Terrano, D. T., Granell, S., Chambers, T. C. (2008). Identification of the Major Phosphorylation Site in Bcl-xL Induced by Microtubule Inhibitors and Analysis of Its Functional Significance. J. Biol. Chem. 283: 35517-35525 [Abstract] [Full Text]  
  • Kim, M.-J., Choi, S.-Y., Park, I.-C., Hwang, S.-G., Kim, C., Choi, Y.-H., Kim, H., Lee, K.-H., Lee, S.-J. (2008). Opposing Roles of c-Jun NH2-Terminal Kinase and p38 Mitogen-Activated Protein Kinase in the Cellular Response to Ionizing Radiation in Human Cervical Cancer Cells. Mol Cancer Res 6: 1718-1731 [Abstract] [Full Text]  
  • Wang, Y., Ausman, L. M., Russell, R. M., Greenberg, A. S., Wang, X.-D. (2008). Increased Apoptosis in High-Fat Diet-Induced Nonalcoholic Steatohepatitis in Rats Is Associated with c-Jun NH2-Terminal Kinase Activation and Elevated Proapoptotic Bax. J. Nutr. 138: 1866-1871 [Abstract] [Full Text]  
  • Stathopoulou, K., Beis, I., Gaitanaki, C. (2008). MAPK signaling pathways are needed for survival of H9c2 cardiac myoblasts under extracellular alkalosis. Am. J. Physiol. Heart Circ. Physiol. 295: H1319-H1329 [Abstract] [Full Text]  
  • Andreeva, A. V., Kutuzov, M. A., Voyno-Yasenetskaya, T. A. (2008). G{alpha}12 is targeted to the mitochondria and affects mitochondrial morphology and motility. FASEB J. 22: 2821-2831 [Abstract] [Full Text]  
  • Hand, S. C., Menze, M. A. (2008). Mitochondria in energy-limited states: mechanisms that blunt the signaling of cell death. J. Exp. Biol. 211: 1829-1840 [Abstract] [Full Text]  
  • Junttila, M. R., Li, S.-P., Westermarck, J. (2008). Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J. 22: 954-965 [Abstract] [Full Text]  
  • Roesslein, M., Frick, M., Auwaerter, V., Humar, M., Goebel, U., Schwer, C., Geiger, K. K., Pahl, H. L., Pannen, B. H. J., Loop, T. (2008). Sevoflurane-Mediated Activation of p38-Mitogen-Activated Stresskinase is Independent of Apoptosis in Jurkat T-Cells. Anesth. Analg. 106: 1150-1160 [Abstract] [Full Text]  
  • Knobloch, J., Schmitz, I., Gotz, K., Schulze-Osthoff, K., Ruther, U. (2008). Thalidomide Induces Limb Anomalies by PTEN Stabilization, Akt Suppression, and Stimulation of Caspase-Dependent Cell Death. Mol. Cell. Biol. 28: 529-538 [Abstract] [Full Text]  
  • Li, L., Abdel Fattah, E., Cao, G., Ren, C., Yang, G., Goltsov, A. A., Chinault, A. C., Cai, W.-W., Timme, T. L., Thompson, T. C. (2008). Glioma Pathogenesis-Related Protein 1 Exerts Tumor Suppressor Activities through Proapoptotic Reactive Oxygen Species c-Jun NH2 Kinase Signaling. Cancer Res. 68: 434-443 [Abstract] [Full Text]  
  • Kolomeichuk, S. N., Bene, A., Upreti, M., Dennis, R. A., Lyle, C. S., Rajasekaran, M., Chambers, T. C. (2008). Induction of Apoptosis by Vinblastine via c-Jun Autoamplification and p53-Independent Down-Regulation of p21WAF1/CIP1. Mol. Pharmacol. 73: 128-136 [Abstract] [Full Text]  
  • Danial, N. N. (2007). BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death. Clin. Cancer Res. 13: 7254-7263 [Abstract] [Full Text]  
  • Ryo, A., Hirai, A., Nishi, M., Liou, Y.-C., Perrem, K., Lin, S.-C., Hirano, H., Lee, S. W., Aoki, I. (2007). A Suppressive Role of the Prolyl Isomerase Pin1 in Cellular Apoptosis Mediated by the Death-associated Protein Daxx. J. Biol. Chem. 282: 36671-36681 [Abstract] [Full Text]  
  • Janssen, K., Pohlmann, S., Janicke, R. U., Schulze-Osthoff, K., Fischer, U. (2007). Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood 110: 3662-3672 [Abstract] [Full Text]  
  • Banadyga, L., Gerig, J., Stewart, T., Barry, M. (2007). Fowlpox Virus Encodes a Bcl-2 Homologue That Protects Cells from Apoptotic Death through Interaction with the Proapoptotic Protein Bak. J. Virol. 81: 11032-11045 [Abstract] [Full Text]  
  • Rubio, S., Quintana, J., Eiroa, J. L., Triana, J., Estevez, F. (2007). Acetyl derivative of quercetin 3-methyl ether-induced cell death in human leukemia cells is amplified by the inhibition of ERK. Carcinogenesis 28: 2105-2113 [Abstract] [Full Text]  
  • Kim, Y., Zhou, P., Qian, L., Chuang, J.-Z., Lee, J., Li, C., Iadecola, C., Nathan, C., Ding, A. (2007). MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival. JEM 204: 2063-2074 [Abstract] [Full Text]  
  • Yanamadala, V., Negoro, H., Gunaratnam, L., Kong, T., Denker, B. M. (2007). G{alpha}12 Stimulates Apoptosis in Epithelial Cells through JNK1-mediated Bcl-2 Degradation and Up-regulation of I{kappa}B{alpha}. J. Biol. Chem. 282: 24352-24363 [Abstract] [Full Text]  
  • Peng, Z., Peng, L., Fan, Y., Zandi, E., Shertzer, H. G., Xia, Y. (2007). A Critical Role for I{kappa}B Kinase beta in Metallothionein-1 Expression and Protection against Arsenic Toxicity. J. Biol. Chem. 282: 21487-21496 [Abstract] [Full Text]  
  • Tran, T. H., Andreka, P., Rodrigues, C. O., Webster, K. A., Bishopric, N. H. (2007). Jun Kinase Delays Caspase-9 Activation by Interaction with the Apoptosome. J. Biol. Chem. 282: 20340-20350 [Abstract] [Full Text]  
  • Kobayashi, S., Lee, S.-H., Meng, X. W., Mott, J. L., Bronk, S. F., Werneburg, N. W., Craig, R. W., Kaufmann, S. H., Gores, G. J. (2007). Serine 64 Phosphorylation Enhances the Antiapoptotic Function of Mcl-1. J. Biol. Chem. 282: 18407-18417 [Abstract] [Full Text]  
  • Wang, M., Zhang, L., Han, X., Yang, J., Qian, J., Hong, S., Samaniego, F., Romaguera, J., Yi, Q. (2007). Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 109: 5455-5462 [Abstract] [Full Text]  
  • Lai, E., Teodoro, T., Volchuk, A. (2007). Endoplasmic Reticulum Stress: Signaling the Unfolded Protein Response. Physiology 22: 193-201 [Abstract] [Full Text]  
  • Lee, S. A., Jung, M. (2007). The Nucleoside Analog Sangivamycin Induces Apoptotic Cell Death in Breast Carcinoma MCF7/Adriamycin-resistant Cells via Protein Kinase C{delta} and JNK Activation. J. Biol. Chem. 282: 15271-15283 [Abstract] [Full Text]  
  • Choe, M. S., Chen, Z., Klass, C. M., Zhang, X., Shin, D. M. (2007). Enhancement of Docetaxel-Induced Cytotoxicity by Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways in Squamous Cell Carcinoma of the Head and Neck. Clin. Cancer Res. 13: 3015-3023 [Abstract] [Full Text]  
  • Dai, Y., Khanna, P., Chen, S., Pei, X.-Y., Dent, P., Grant, S. (2007). Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood 109: 4415-4423 [Abstract] [Full Text]  
  • Vijapurkar, U., Wang, W., Herbst, R. (2007). Potentiation of Kinesin Spindle Protein Inhibitor-Induced Cell Death by Modulation of Mitochondrial and Death Receptor Apoptotic Pathways. Cancer Res. 67: 237-245 [Abstract] [Full Text]  
  • Liu, X., Zhu, Y., Dai, S., White, J., Peyerl, F., Kappler, J. W., Marrack, P. (2006). Bcl-xl does not have to bind Bax to protect T cells from death. JEM 203: 2953-2961 [Abstract] [Full Text]  
  • Bogoyevitch, M. A., Kobe, B. (2006). Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases. Microbiol. Mol. Biol. Rev. 70: 1061-1095 [Abstract] [Full Text]  
  • O'Neill, R. A., Bhamidipati, A., Bi, X., Deb-Basu, D., Cahill, L., Ferrante, J., Gentalen, E., Glazer, M., Gossett, J., Hacker, K., Kirby, C., Knittle, J., Loder, R., Mastroieni, C., MacLaren, M., Mills, T., Nguyen, U., Parker, N., Rice, A., Roach, D., Suich, D., Voehringer, D., Voss, K., Yang, J., Yang, T., Vander Horn, P. B. (2006). Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc. Natl. Acad. Sci. USA 103: 16153-16158 [Abstract] [Full Text]  
  • Cui, J., Han, S.-Y., Wang, C., Su, W., Harshyne, L., Holgado-Madruga, M., Wong, A. J. (2006). c-Jun NH2-Terminal Kinase 2{alpha}2 Promotes the Tumorigenicity of Human Glioblastoma Cells.. Cancer Res. 66: 10024-10031 [Abstract] [Full Text]  
  • Cai, B., Chang, S. H., Becker, E. B. E., Bonni, A., Xia, Z. (2006). p38 MAP Kinase Mediates Apoptosis through Phosphorylation of BimEL at Ser-65. J. Biol. Chem. 281: 25215-25222 [Abstract] [Full Text]  
  • Lin, S. S., Bassik, M. C., Suh, H., Nishino, M., Arroyo, J. D., Hahn, W. C., Korsmeyer, S. J., Roberts, T. M. (2006). PP2A Regulates BCL-2 Phosphorylation and Proteasome-mediated Degradation at the Endoplasmic Reticulum. J. Biol. Chem. 281: 23003-23012 [Abstract] [Full Text]  
  • Hsu, Y.-L., Cho, C.-Y., Kuo, P.-L., Huang, Y.-T., Lin, C.-C. (2006). Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Induces Apoptosis and Cell Cycle Arrest in A549 Cells through p53 Accumulation via c-Jun NH2-Terminal Kinase-Mediated Phosphorylation at Serine 15 in Vitro and in Vivo. J. Pharmacol. Exp. Ther. 318: 484-494 [Abstract] [Full Text]  
  • Ruiz, S., Krupnik, Y., Keating, M., Chandra, J., Palladino, M., McConkey, D. (2006). The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.. Molecular Cancer Therapeutics 5: 1836-1843 [Abstract] [Full Text]  
  • Deng, X., Gao, F., Flagg, T., Anderson, J., May, W. S. (2006). Bcl2's Flexible Loop Domain Regulates p53 Binding and Survival. Mol. Cell. Biol. 26: 4421-4434 [Abstract] [Full Text]  
  • Arita, Y., Harkness, S. H., Kazzaz, J. A., Koo, H.-c., Joseph, A., Melendez, J.A., Davis, J. M., Chander, A., Li, Y. (2006). Mitochondrial localization of catalase provides optimal protection from H2O2-induced cell death in lung epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L978-L986 [Abstract] [Full Text]  
  • Xu, Y., Huang, S., Liu, Z.-G., Han, J. (2006). Poly(ADP-ribose) Polymerase-1 Signaling to Mitochondria in Necrotic Cell Death Requires RIP1/TRAF2-mediated JNK1 Activation. J. Biol. Chem. 281: 8788-8795 [Abstract] [Full Text]  
  • Farley, N., Pedraza-Alva, G., Serrano-Gomez, D., Nagaleekar, V., Aronshtam, A., Krahl, T., Thornton, T., Rincon, M. (2006). p38 Mitogen-Activated Protein Kinase Mediates the Fas-Induced Mitochondrial Death Pathway in CD8+ T Cells.. Mol. Cell. Biol. 26: 2118-2129 [Abstract] [Full Text]  
  • Nishiyama, A., Dey, A., Miyazaki, J.-i., Ozato, K. (2006). Brd4 Is Required for Recovery from Antimicrotubule Drug-induced Mitotic Arrest: Preservation of Acetylated Chromatin. Mol. Biol. Cell 17: 814-823 [Abstract] [Full Text]  
  • Hosono, T., Fukao, T., Ogihara, J., Ito, Y., Shiba, H., Seki, T., Ariga, T. (2005). Diallyl Trisulfide Suppresses the Proliferation and Induces Apoptosis of Human Colon Cancer Cells through Oxidative Modification of {beta}-Tubulin. J. Biol. Chem. 280: 41487-41493 [Abstract] [Full Text]  
  • Stankiewicz, A. R., Lachapelle, G., Foo, C. P. Z., Radicioni, S. M., Mosser, D. D. (2005). Hsp70 Inhibits Heat-induced Apoptosis Upstream of Mitochondria by Preventing Bax Translocation. J. Biol. Chem. 280: 38729-38739 [Abstract] [Full Text]  
  • Abarzua, F., Sakaguchi, M., Takaishi, M., Nasu, Y., Kurose, K., Ebara, S., Miyazaki, M., Namba, M., Kumon, H., Huh, N.-h. (2005). Adenovirus-Mediated Overexpression of REIC/Dkk-3 Selectively Induces Apoptosis in Human Prostate Cancer Cells through Activation of c-Jun-NH2-Kinase. Cancer Res. 65: 9617-9622 [Abstract] [Full Text]  
  • Vorburger, S. A., Hetrakul, N., Xia, W., Wilson-Heiner, M., Mirza, N., Pollock, R. E., Feig, B., Swisher, S. G., Hunt, K. K. (2005). Gene therapy with E2F-1 up-regulates the protein kinase PKR and inhibits growth of leiomyosarcoma in vivo. Molecular Cancer Therapeutics 4: 1710-1716 [Abstract] [Full Text]  
  • Cuomo, M. E., Knebel, A., Platt, G., Morrice, N., Cohen, P., Mittnacht, S. (2005). Regulation of Microfilament Organization by Kaposi Sarcoma-associated Herpes Virus-cyclin{middle dot}CDK6 Phosphorylation of Caldesmon. J. Biol. Chem. 280: 35844-35858 [Abstract] [Full Text]  
  • Nishigaki, K., Hanson, C., Thompson, D., Yugawa, T., Ruscetti, S. (2005). Activation of the Jun N-Terminal Kinase Pathway by Friend Spleen Focus-Forming Virus and Its Role in the Growth and Survival of Friend Virus-Induced Erythroleukemia Cells. J. Virol. 79: 12752-12762 [Abstract] [Full Text]  
  • Kondo, E., Miyake, T., Shibata, M., Kimura, T., Iwagaki, H., Nakamura, S.-i., Tanaka, T., Ohara, N., Ichimura, K., Oka, T., Yanai, H., Shibasaki, F., Yoshino, T. (2005). Expression of Phosphorylated Ser70 of Bcl-2 Correlates with Malignancy in Human Colorectal Neoplasms. Clin. Cancer Res. 11: 7255-7263 [Abstract] [Full Text]  
  • Liu, J., Huang, Q., Higdon, J., Liu, W., Xie, T., Yamashita, T., Cheon, K., Cheng, C., Zuo, J. (2005). Distinct gene expression profiles and reduced JNK signaling in retinitis pigmentosa caused by RP1 mutations. Hum Mol Genet 14: 2945-2958 [Abstract] [Full Text]  
  • Kaiser, R. A., Liang, Q., Bueno, O., Huang, Y., Lackey, T., Klevitsky, R., Hewett, T. E., Molkentin, J. D. (2005). Genetic Inhibition or Activation of JNK1/2 Protects the Myocardium from Ischemia-Reperfusion-induced Cell Death in Vivo. J. Biol. Chem. 280: 32602-32608 [Abstract] [Full Text]  
  • Xing, Y., Igarashi, H., Wang, X., Sakaguchi, N. (2005). Protein phosphatase subunit G5PR is needed for inhibition of B cell receptor-induced apoptosis. JEM 202: 707-719 [Abstract] [Full Text]  
  • de Graauw, M., Tijdens, I., Cramer, R., Corless, S., Timms, J. F., van de Water, B. (2005). Heat Shock Protein 27 Is the Major Differentially Phosphorylated Protein Involved in Renal Epithelial Cellular Stress Response and Controls Focal Adhesion Organization and Apoptosis. J. Biol. Chem. 280: 29885-29898 [Abstract] [Full Text]  
  • Gururajan, M., Chui, R., Karuppannan, A. K., Ke, J., Jennings, C. D., Bondada, S. (2005). c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106: 1382-1391 [Abstract] [Full Text]  
  • Panaretakis, T., Laane, E., Pokrovskaja, K., Bjorklund, A.-C., Moustakas, A., Zhivotovsky, B., Heyman, M., Shoshan, M. C., Grander, D. (2005). Doxorubicin Requires the Sequential Activation of Caspase-2, Protein Kinase C{delta}, and c-Jun NH2-terminal Kinase to Induce Apoptosis. Mol. Biol. Cell 16: 3821-3831 [Abstract] [Full Text]  
  • Hua, F., Cornejo, M. G., Cardone, M. H., Stokes, C. L., Lauffenburger, D. A. (2005). Effects of Bcl-2 Levels on Fas Signaling-Induced Caspase-3 Activation: Molecular Genetic Tests of Computational Model Predictions. J. Immunol. 175: 985-995 [Abstract] [Full Text]  
  • Yang, M. Y., Lau, S. S., Monks, T. J. (2005). 2,3,5-tris(Glutathion-S-yl)hydroquinone (TGHQ)-Mediated Apoptosis of Human Promyelocytic Leukemia Cells Is Preceded by Mitochondrial Cytochrome c Release in the Absence of a Decrease in the Mitochondrial Membrane Potential. Toxicol Sci 86: 92-100 [Abstract] [Full Text]  
  • Muller, I. M., Dirsch, V. M., Rudy, A., Lopez-Anton, N., Pettit, G. R., Vollmar, A. M. (2005). Cephalostatin 1 Inactivates Bcl-2 by Hyperphosphorylation Independent of M-Phase Arrest and DNA Damage. Mol. Pharmacol. 67: 1684-1689 [Abstract] [Full Text]  
  • Hahn, M., Li, W., Yu, C., Rahmani, M., Dent, P., Grant, S. (2005). Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Molecular Cancer Therapeutics 4: 457-470 [Abstract] [Full Text]  
  • Dai, Y., Rahmani, M., Pei, X.-Y., Khanna, P., Han, S. I., Mitchell, C., Dent, P., Grant, S. (2005). Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 105: 1706-1716 [Abstract] [Full Text]  
  • Zu, K., Hawthorn, L., Ip, C. (2005). Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by {alpha}-tocopheryl succinate in human prostate cancer cells. Molecular Cancer Therapeutics 4: 43-50 [Abstract] [Full Text]  
  • Eminel, S., Klettner, A., Roemer, L., Herdegen, T., Waetzig, V. (2004). JNK2 Translocates to the Mitochondria and Mediates Cytochrome c Release in PC12 Cells in Response to 6-Hydroxydopamine. J. Biol. Chem. 279: 55385-55392 [Abstract] [Full Text]  
  • Melendez, J., Turner, C., Avraham, H., Steinberg, S. F., Schaefer, E., Sussman, M. A. (2004). Cardiomyocyte Apoptosis Triggered by RAFTK/pyk2 via Src Kinase Is Antagonized by Paxillin. J. Biol. Chem. 279: 53516-53523 [Abstract] [Full Text]  
  • Pei, X.-Y., Dai, Y., Grant, S. (2004). The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Molecular Cancer Therapeutics 3: 1513-1524 [Abstract] [Full Text]  
  • Mehrotra, S., Chhabra, A., Chattopadhyay, S., Dorsky, D. I., Chakraborty, N. G., Mukherji, B. (2004). Rescuing Melanoma Epitope-Specific Cytolytic T Lymphocytes from Activation-Induced Cell Death, by SP600125, an Inhibitor of JNK: Implications in Cancer Immunotherapy. J. Immunol. 173: 6017-6024 [Abstract] [Full Text]  
  • Kurinna, S. M., Tsao, C. C., Nica, A. F., Jiffar, T., Ruvolo, P. P. (2004). Ceramide Promotes Apoptosis in Lung Cancer-Derived A549 Cells by a Mechanism Involving c-Jun NH2-Terminal Kinase. Cancer Res. 64: 7852-7856 [Abstract] [Full Text]  
  • Aikin, R., Maysinger, D., Rosenberg, L. (2004). Cross-Talk between Phosphatidylinositol 3-Kinase/AKT and c-Jun NH2-Terminal Kinase Mediates Survival of Isolated Human Islets. Endocrinology 145: 4522-4531 [Abstract] [Full Text]  
  • MacCorkle, R. A., Tan, T.-H. (2004). Inhibition of JNK2 Disrupts Anaphase and Produces Aneuploidy in Mammalian Cells. J. Biol. Chem. 279: 40112-40121 [Abstract] [Full Text]  
  • Matsukawa, J., Matsuzawa, A., Takeda, K., Ichijo, H. (2004). The ASK1-MAP Kinase Cascades in Mammalian Stress Response. J Biochem 136: 261-265 [Abstract] [Full Text]  
  • Mc Gee, M. M., Greene, L. M., Ledwidge, S., Campiani, G., Nacci, V., Lawler, M., Williams, D. C., Zisterer, D. M. (2004). Selective Induction of Apoptosis by the Pyrrolo-1,5-benzoxazepine 7-[{Dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia Cells Occurs via the c-Jun NH2-Terminal Kinase-Dependent Phosphorylation and Inactivation of Bcl-2 and Bcl-XL. J. Pharmacol. Exp. Ther. 310: 1084-1095 [Abstract] [Full Text]  
  • Kuznetsov, G., Towle, M. J., Cheng, H., Kawamura, T., TenDyke, K., Liu, D., Kishi, Y., Yu, M. J., Littlefield, B. A. (2004). Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389. Cancer Res. 64: 5760-5766 [Abstract] [Full Text]  
  • Jacobs-Helber, S. M., Sawyer, S. T. (2004). Jun N-terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell lines. Blood 104: 696-703 [Abstract] [Full Text]  
  • Kanda, H., Miura, M. (2004). Regulatory Roles of JNK in Programmed Cell Death. J Biochem 136: 1-6 [Abstract] [Full Text]  
  • Kuo, C.-C., Hsieh, H.-P., Pan, W.-Y., Chen, C.-P., Liou, J.-P., Lee, S.-J., Chang, Y.-L., Chen, L.-T., Chen, C.-T., Chang, J.-Y. (2004). BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo. Cancer Res. 64: 4621-4628 [Abstract] [Full Text]  
  • Kang, P. M., Yue, P., Liu, Z., Tarnavski, O., Bodyak, N., Izumo, S. (2004). Alterations in apoptosis regulatory factors during hypertrophy and heart failure. Am. J. Physiol. Heart Circ. Physiol. 287: H72-H80 [Abstract] [Full Text]  
  • Derouet, M., Thomas, L., Cross, A., Moots, R. J., Edwards, S. W. (2004). Granulocyte Macrophage Colony-stimulating Factor Signaling and Proteasome Inhibition Delay Neutrophil Apoptosis by Increasing the Stability of Mcl-1. J. Biol. Chem. 279: 26915-26921 [Abstract] [Full Text]  
  • Zhang, R., Al-Lamki, R., Bai, L., Streb, J. W., Miano, J. M., Bradley, J., Min, W. (2004). Thioredoxin-2 Inhibits Mitochondria-Located ASK1-Mediated Apoptosis in a JNK-Independent Manner. Circ. Res. 94: 1483-1491 [Abstract] [Full Text]  
  • Takenaka, Y., Fukumori, T., Yoshii, T., Oka, N., Inohara, H., Kim, H.-R. C., Bresalier, R. S., Raz, A. (2004). Nuclear Export of Phosphorylated Galectin-3 Regulates Its Antiapoptotic Activity in Response to Chemotherapeutic Drugs. Mol. Cell. Biol. 24: 4395-4406 [Abstract] [Full Text]  
  • Davison, K., Mann, K. K., Waxman, S., Miller, W. H. Jr (2004). JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103: 3496-3502 [Abstract] [Full Text]  
  • Rosini, P., De Chiara, G., Bonini, P., Lucibello, M., Marcocci, M. E., Garaci, E., Cozzolino, F., Torcia, M. (2004). Nerve Growth Factor-dependent Survival of CESS B Cell Line Is Mediated by Increased Expression and Decreased Degradation of MAPK Phosphatase 1. J. Biol. Chem. 279: 14016-14023 [Abstract] [Full Text]  
  • Maggio, S. C., Rosato, R. R., Kramer, L. B., Dai, Y., Rahmani, M., Paik, D. S., Czarnik, A. C., Payne, S. G., Spiegel, S., Grant, S. (2004). The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells. Cancer Res. 64: 2590-2600 [Abstract] [Full Text]  
  • Dai, Y., Pei, X.-Y., Rahmani, M., Conrad, D. H., Dent, P., Grant, S. (2004). Interruption of the NF-{kappa}B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 103: 2761-2770 [Abstract] [Full Text]  
  • Du, L., Lyle, C. S., Obey, T. B., Gaarde, W. A., Muir, J. A., Bennett, B. L., Chambers, T. C. (2004). Inhibition of Cell Proliferation and Cell Cycle Progression by Specific Inhibition of Basal JNK Activity: EVIDENCE THAT MITOTIC Bcl-2 PHOSPHORYLATION IS JNK-INDEPENDENT. J. Biol. Chem. 279: 11957-11966 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Korsmeyer, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Korsmeyer, S. J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»